We are live on ! Find out more
FCMI

Foresite Capital Management II Portfolio holdings

AUM $29.2M
1-Year Est. Return 44.84%
This Fund
S&P 500
This Quarter Est. Return
-4.5%
1 Year Est. Return
+44.84%
3 Year Est. Return
-66.21%
5 Year Est. Return
-36.36%
10 Year Est. Return
–
AUM
$285M
AUM Growth
+$116M
Cap. Flow
+$64.1M
Cap. Flow %
22.48%
Top 10 Hldgs %
86.17%
Holding
26
New
10
Increased
5
Reduced
4
Closed
4

Top Buys

Rank Stock Value
1
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$69.6M
2
ADAP
Adaptimmune Therapeutics
ADAP
+$30.2M
3
UAM
Universal American Corp
UAM
+$29.3M
4
AERI
Aerie Pharmaceuticals
AERI
+$10.9M
5
ALDR
Alder Biopharmaceuticals
ALDR
+$6.82M

Top Sells

Rank Stock Value
1
LRMR icon
Larimar Therapeutics
LRMR
+$94.1M
2
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$7.52M
3
AGRX
Agile Therapeutics
AGRX
+$4.37M
4
TTOO
T2 Biosystems, Inc
TTOO
+$3.62M
5
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$2.59M

Sector Composition

Rank Sector Weight
1 Healthcare 91.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KDNY
1
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$63.9M 22.42%
+421,347
New +$69.6M
ADAP
2
DELISTED
Adaptimmune Therapeutics
ADAP
$32.2M 11.3%
+1,757,268
New +$30.2M
UAM
3
DELISTED
Universal American Corp
UAM
$28.5M 10%
+2,814,883
New +$29.3M
LRMR icon
4
Larimar Therapeutics
LRMR
$416M
$28.1M 9.86%
67,608
-225,013
-77% -$94.1M
EPZM
5
DELISTED
Epizyme, Inc
EPZM
$21.5M 7.56%
897,863
+143,057
+19% +$2.75M
OREX
6
DELISTED
Orexigen Therapeutics, Inc.
OREX
$20.8M 7.3%
420,005
– –
ALDR
7
DELISTED
Alder Biopharmaceuticals
ALDR
$18.3M 6.41%
344,770
+187,639
+119% +$6.82M
AERI
8
DELISTED
Aerie Pharmaceuticals
AERI
$14.2M 4.99%
805,217
+595,150
+283% +$10.9M
RGLS
9
DELISTED
Regulus Therapeutics
RGLS
$9.8M 3.44%
7,448
+3,867
+108% +$6.24M
ARDX icon
10
Ardelyx
ARDX
$1.24B
$8.26M 2.9%
+517,290
New +$6.52M
NSTG
11
DELISTED
NanoString Technologies, Inc.
NSTG
$7.16M 2.51%
+464,486
New +$6.21M
BDSI
12
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$5.67M 1.99%
712,278
+264,400
+59% +$2.27M
SCYX icon
13
SCYNEXIS
SCYX
$37M
$5.52M 1.94%
7,852
-435
-5% -$312K
JUNO
14
DELISTED
Juno Therapeutics, Inc.
JUNO
$4.88M 1.71%
91,575
– –
QTNT
15
DELISTED
Quotient Limited Ordinary Shares
QTNT
$4.41M 1.55%
7,459
-704
-9% -$434K
BITI
16
DELISTED
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
$3.77M 1.32%
+188,900
New +$3.94M
NVET
17
DELISTED
Nexvet Biopharma plc Ordinary Shares
NVET
$3.52M 1.24%
708,332
– –
SIOX
18
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$1.32M 0.47%
+8,125
New +$1.38M
NDRM
19
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$1.14M 0.4%
+74,385
New +$1.05M
XLRN
20
DELISTED
Acceleron Pharma
XLRN
$984K 0.35%
+31,100
New +$1M
OREX
21
CALL
DELISTED
Orexigen Therapeutics, Inc.
OREX
$594K 0.21%
+12,000
New +$717K
AGRX
22
DELISTED
Agile Therapeutics
AGRX
$428K 0.15%
25
-205
-89% -$4.37M
SGMO
23
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-165,000
Closed -$2.59M
TTOO
24
DELISTED
T2 Biosystems, Inc
TTOO
– –
-47
Closed -$3.62M
RXDX
25
DELISTED
Ignyta, Inc.
RXDX
– –
-185,220
Closed -$1.84M
1
2

Similar funds

AG
Appleton Group Appleton, Wisconsin $28.6M AUM 32.21% 1-Year Est. Return
SAM
Sandbar Asset Management London, United Kingdom $30.5M AUM 46.07% 1-Year Est. Return
AC
Amia Capital London, United Kingdom $32.1M AUM 0.56% 1-Year Est. Return
QI
Qualcomm Inc San Diego, California $32.1M AUM 5.35% 1-Year Est. Return
TAAM
Top Ace Asset Management Hong Kong $25.3M AUM 23.27% 1-Year Est. Return
NAM
Nationwide Asset Management Columbus, Ohio $25.1M AUM 13.37% 1-Year Est. Return
MSKCC
Memorial Sloan Kettering Cancer Center New York $24.6M AUM 10.16% 1-Year Est. Return
BRC
Bishop Rock Capital New York $24.3M AUM 20.73% 1-Year Est. Return

Foresite Capital Management II's Q2 2015 Portfolio in Review

As of Q2 2015, Foresite Capital Management II held 26 positions worth $285M, up 69% from $169M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Foresite Capital Management II deployed $64.1M of net new capital in Q2 2015, opening 10 new positions and adding to 5 existing holdings. Its largest new stake was Chinook Therapeutics, Inc. Common Stock: 421,347 shares worth $63.9M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 84% a quarter earlier.

On the sell side, the largest reduction was Larimar Therapeutics, an estimated $94.1M trimmed.

  • Foresite Capital Management II's largest Q2 2015 buy was Chinook Therapeutics, Inc. Common Stock: 421,347 shares worth $63.9M.
  • Foresite Capital Management II added most to Aerie Pharmaceuticals in Q2 2015, an estimated $10.9M increase.
  • Foresite Capital Management II's biggest Q2 2015 reduction was Larimar Therapeutics, cutting an estimated $94.1M.
  • Foresite Capital Management II fully exited AUSPEX PHARMACEUTICALS INC COM STK (DE) in Q2 2015, selling an estimated $7.52M.
  • Foresite Capital Management II's ten largest holdings make up 86% of its $285M portfolio in Q2 2015.
  • Foresite Capital Management II opened 10 new positions and closed 4 in Q2 2015.
  • Foresite Capital Management II's portfolio value rose 69% quarter-over-quarter to $285M.

Based on Foresite Capital Management II's 13F filing for Q2 2015, filed 14 Aug 2015.